Biohaven - BHVN Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 1-year target prices for Biohaven's stock. Their BHVN share price forecasts range from $21.00 to $160.00. On average, they predict the company's stock price to reach $94.59 in the next twelve months. This suggests a possible upside of 465.1% from the stock's current price.
View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts.

Biohaven's stock was trading at $137.81 on January 1st, 2022. Since then, BHVN shares have decreased by 87.9% and is now trading at $16.74.
View the best growth stocks for 2022 here.

Biohaven saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 2,920,000 shares, an increase of 8.6% from the October 15th total of 2,690,000 shares. Based on an average daily trading volume, of 2,610,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 11.3% of the shares of the company are sold short.
View Biohaven's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our BHVN earnings forecast.

Biohaven Ltd. (NYSE:BHVN) posted its quarterly earnings results on Wednesday, November, 9th. The company reported ($1.75) earnings per share for the quarter, topping analysts' consensus estimates of ($2.53) by $0.78.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.26%), UBS Oconnor LLC (5.55%), State Street Corp (3.28%), Farallon Capital Management LLC (3.20%), Vanguard Group Inc. (2.11%) and Armistice Capital LLC (2.10%). Insiders that own company stock include Declan Doogan, Elyse Stock, Eric Aguiar, George C Clark, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Matthew Buten, Robert Berman, Vlad Coric and William A Jones Jr.
View institutional ownership trends.

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BHVN stock can currently be purchased for approximately $16.74.

Biohaven (NYSE:BHVN) has a market capitalization of $1.14 billion and generates $462.51 million in revenue each year. The company earns $-846,590,000.00 in net income (profit) each year or ($13.94) on an earnings per share basis.

The company employs 928 workers across the globe.

Biohaven's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at (203) 404-0410 or via email at jennifer.porcelli@biohavenpharma.com.